Payment overview · 2025
General Payments
$487.40
22 reported records · 9 companies
Healthcare provider profile · identity verified
Alan Kravatz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEVITTOWN, PA · NPI 1356369623
Verified facts
What the public records show
CMS Open Payments records show Alan Kravatz, MD received $487.40 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.64 | 34.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.36 | 14.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.82 | 12.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.21 | 10.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.70 | 7.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.08 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.00 | 6.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.67 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.92 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.40 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.70 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 363 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 108 |
| Eliquis | Apixaban | 363 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 82 |
| Metformin Hcl | Metformin Hcl | 319 | 82 |
| Sertraline Hcl | Sertraline Hcl | 265 | 55 |
| Losartan Potassium | Losartan Potassium | 264 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 68 |
| Gabapentin | Gabapentin | 256 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 43 |
| Alprazolam | Alprazolam | 153 | 22 |
| Omeprazole | Omeprazole | 148 | 42 |
| Lisinopril | Lisinopril | 144 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 30 |
| Potassium Chloride | Potassium Chloride | 134 | 25 |
| Valsartan | Valsartan | 133 | 33 |
| Trazodone Hcl | Trazodone Hcl | 115 | 34 |
| Montelukast Sodium | Montelukast Sodium | 112 | 24 |
| Glimepiride | Glimepiride | 111 | 30 |
| Carvedilol | Carvedilol | 110 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 33 |
| Furosemide | Furosemide | 104 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 28 |
| Famotidine | Famotidine | 96 | 21 |
| Mounjaro | Tirzepatide | 96 | 14 |
| Simvastatin | Simvastatin | 95 | 26 |
| Ezetimibe | Ezetimibe | 94 | 29 |
| Allopurinol | Allopurinol | 92 | 22 |
| Jardiance | Empagliflozin | 86 | 15 |
| Lorazepam | Lorazepam | 85 | 23 |
| Mirtazapine | Mirtazapine | 85 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 17 |
| Xarelto | Rivaroxaban | 79 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 21 |
| Tramadol Hcl | Tramadol Hcl | 76 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 20 |
| Trulicity | Dulaglutide | 75 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 22 |
| Donepezil Hcl | Donepezil Hcl | 74 | 12 |
| Januvia | Sitagliptin Phosphate | 73 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 34 |
| Finasteride | Finasteride | 66 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | suppressed |
| Azithromycin | Azithromycin | 61 | 49 |
| Atenolol | Atenolol | 58 | 13 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Ondansetron Odt | Ondansetron | 54 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 11 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Meloxicam | Meloxicam | 39 | 21 |
| Torsemide | Torsemide | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 13 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 28 |
| Ozempic | Semaglutide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Compro | Prochlorperazine | 31 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Nadolol | Nadolol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Prednisone | Prednisone | 22 | 15 |
| Primidone | Primidone | 22 | suppressed |
| Procrit | Epoetin Alfa | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Xtampza Er | Oxycodone Myristate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 12 |
| Carvedilol Er | Carvedilol Phosphate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.40 · 22 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, ELIQUIS, FARXIGA, FASENRA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error